Ind Swift Laboratories Ltd vs Pharmaids Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 144.45 as of 06 May 15:30 . The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 0 on March 2021 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Pharmaids Pharmaceuticals Ltd changed from 89.4 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 392.34 crore on March 2022 to ₹ 425.72 crore on March 2021 . This represents a CAGR of 1.65% over 5 yearsThe Market Cap of Pharmaids Pharmaceuticals Ltd changed from ₹ 12.9 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The revenue of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ 5.51 crore as compare to the Sep '25 revenue of ₹ 11.63 crore. This represent the decline of -52.62% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The ebitda of Pharmaids Pharmaceuticals Ltd for the Dec '25 is ₹ -2.83 crore as compare to the Sep '25 ebitda of ₹ -2.3 crore. This represent the growth of 23.04% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The net profit of Pharmaids Pharmaceuticals Ltd changed from ₹ -3.12 crore to ₹ -2.65 crore over 7 quarters. This represents a CAGR of -8.91% The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Pharmaids Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Limited, incorporated in March, 1989 at Hyderabad, Telangana were suppliers of Quality Grade range of speciality chemicals, skin care, hospital care and generic products in the areas of Orthopedic, Neuro and Gastro etc.
The technical team used quality proven chemical compounds and standard processing methods maintaining proper hygiene standards.The Company is engaged in the business of contract research and manufacturing services. Emergent Bio Naturals Limited (EBNL) was amalgamated with the Company in 2019-20 and the Scheme of Amalgamation was effective on September 27, 2019.
Pursuant to the Scheme, 69,05,734 Equity Shares were allotted to Shareholders of Emergent Bio Naturals Limited on November 27, 2019. The Company acquired 25.5% stake as 1st tranche in Anugraha Chemicals, a Partnership Firm, registered under Karnataka Partnership Rules, 1954 on February 1, 2023.

FAQs for the comparison of Ind-Swift Laboratories Ltd and Pharmaids Pharmaceuticals Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Pharmaids Pharmaceuticals Ltd?

Market cap of Ind-Swift Laboratories Ltd is 1,254 Cr while Market cap of Pharmaids Pharmaceuticals Ltd is 105 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Pharmaids Pharmaceuticals Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Pharmaids Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Pharmaids Pharmaceuticals Ltd?

As of May 6, 2026, the Ind-Swift Laboratories Ltd stock price is INR ₹144.45. On the other hand, Pharmaids Pharmaceuticals Ltd stock price is INR ₹29.89.

How do dividend payouts of Ind-Swift Laboratories Ltd and Pharmaids Pharmaceuticals Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Pharmaids Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.